ArticleBMC nephrology2025
Chronic kidney disease in Romania: national adjusted prevalence, risk factors, and temporal trends in high-risk groups.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a growing global health concern, associated with substantial morbidity and mortality. In Romania, national-level data on CKD prevalence remain limited. This study aimed to estimate the prevalence and risk factors of CKD in Romania using two independent cohorts: a general population cohort (2007–2008) and a targeted high-risk cohort (2023) consisting of individuals with hypertension, diabetes, or cardiovascular disease.
methodsThe general population cohort (N = 26,831) was derived from a national health survey in Iassy. The 2023 targeted cohort (N = 2,247) was screened using a structured, software-assisted protocol by general practitioners in Bucharest. CKD was defined as eGFR < 60 mL/min/1.73 m² and/or albuminuria ≥ 30 mg/g; the 3-month chronicity criterion was applied only in the 2023 cohort. Risk categories for CKD progression (moderate, high, very high) were assigned according to KDIGO definitions.
resultsThe standardized national prevalence of CKD was 8.97%. CKD prevalence in the high-risk 2023 cohort was 27%, compared to 18% in a matched at-risk group from the 2007–2008 cohort. Most CKD cases were at moderate risk, though the proportion of very high-risk individuals increased over time (7.6% to 10.5%). Targeted screening doubled detection efficiency (number needed to screen = 4 vs. 7).
conclusionCKD is a public health issue in Romania, particularly among individuals with cardiometabolic comorbidities. Targeted screening improves detection efficiency and may serve as a cost-effective strategy to reduce disease burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.